BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...Tkach Tuzman Yale University University of Toronto Bright Angel Therapeutics Inc. St. Jude Children's Research Hospital Sun...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

...al. Nat. Commun.; published online Oct. 1, 2020doi:10.1038/s41467-020-18708-xCONTACT: Patrick Ryan Potts, St. Jude Children’s Research Hospital, Memphis, Tenn.email: ryan.potts@stjude.org Claire Quang St. Jude Children's Research Hospital Cancer Neuroendocrine...
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...Wisconsin-Madison, and is now the chair of the department of chemical biology and therapeutics at St. Jude Children's Research Hospital...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...cytometry technology enables multiplexed detection of over 50 surface and intracellular markers from single cells. BioCentury Staff St. Jude Children's Research Hospital Blue...
BioCentury | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

...were thus less responsive to immunotherapies such as checkpoint inhibitors or neoantigen-based T cell therapies. St. Jude Children's Research Hospital...
...to neoantigens is more likely to target a greater proportion of the mutations." Paul Thomas, St. Jude Children's Research Hospital...
...6; HLA - Human leukocyte antigen; RUNX1 (AML1) - Runt-related transcription factor 1 Inhua Muijrers-Chen, Associate Editor St. Jude Children's Research Hospital ETS...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...targets of entrectinib; in a Ph I trial, the gene fusions were associated with response St. Jude Children's Research Hospital...
BioCentury | Apr 17, 2019
Clinical News

St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

...to develop and commercialize the ex vivo lentiviral gene therapy, which it calls MB-107, from St. Jude Children's Research Hospital...
...trading. Mustang was off $0.15 to $2.66 on Wednesday. Brian Moy, Assistant Editor LVXSCID gene therapy Mustang Bio Inc. St. Jude Children's Research Hospital...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Neurology

...23, 2018 doi:10.1038/s41467-018-06703-2 CONTACT: Suzanne Jackowski, St. Jude Children’s Research Hospital, Memphis, Tenn. email: suzanne.jackowski@stjude.org Claire Quang St. Jude Children's Research Hospital Pantothenate...
BioCentury | Sep 28, 2018
Company News

Tessa, St. Jude partner to develop cellular immunotherapies for pediatric brain cancers

...Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat...
...company. Tessa Therapeutics Pte. Ltd., Singapore St. Jude Children's Research Hospital, Memphis, Tenn. Business: Cancer Mary Romeo Epstein-Barr Virus-Specific T Cells (EBVST) St. Jude Children's Research Hospital Tessa...
BioCentury | Aug 17, 2018
Company News

Mustang licenses immunodeficiency gene therapy from St. Jude

...commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital...
...St. Jude Children's Research Hospital, Memphis, Tenn. Mustang Bio Inc. (NASDAQ:MBIO), New York, N.Y. Business: Gene/Cell therapy Sandi Wong Mustang Bio Inc. St. Jude Children's Research Hospital Interleukin-2...
Items per page:
1 - 10 of 165
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...Tkach Tuzman Yale University University of Toronto Bright Angel Therapeutics Inc. St. Jude Children's Research Hospital Sun...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

...al. Nat. Commun.; published online Oct. 1, 2020doi:10.1038/s41467-020-18708-xCONTACT: Patrick Ryan Potts, St. Jude Children’s Research Hospital, Memphis, Tenn.email: ryan.potts@stjude.org Claire Quang St. Jude Children's Research Hospital Cancer Neuroendocrine...
BioCentury | Mar 21, 2020
Finance

Design debuts with $45M series A, portfolio against repeat expansions

...Wisconsin-Madison, and is now the chair of the department of chemical biology and therapeutics at St. Jude Children's Research Hospital...
BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...cytometry technology enables multiplexed detection of over 50 surface and intracellular markers from single cells. BioCentury Staff St. Jude Children's Research Hospital Blue...
BioCentury | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

...were thus less responsive to immunotherapies such as checkpoint inhibitors or neoantigen-based T cell therapies. St. Jude Children's Research Hospital...
...to neoantigens is more likely to target a greater proportion of the mutations." Paul Thomas, St. Jude Children's Research Hospital...
...6; HLA - Human leukocyte antigen; RUNX1 (AML1) - Runt-related transcription factor 1 Inhua Muijrers-Chen, Associate Editor St. Jude Children's Research Hospital ETS...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...targets of entrectinib; in a Ph I trial, the gene fusions were associated with response St. Jude Children's Research Hospital...
BioCentury | Apr 17, 2019
Clinical News

St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

...to develop and commercialize the ex vivo lentiviral gene therapy, which it calls MB-107, from St. Jude Children's Research Hospital...
...trading. Mustang was off $0.15 to $2.66 on Wednesday. Brian Moy, Assistant Editor LVXSCID gene therapy Mustang Bio Inc. St. Jude Children's Research Hospital...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Neurology

...23, 2018 doi:10.1038/s41467-018-06703-2 CONTACT: Suzanne Jackowski, St. Jude Children’s Research Hospital, Memphis, Tenn. email: suzanne.jackowski@stjude.org Claire Quang St. Jude Children's Research Hospital Pantothenate...
BioCentury | Sep 28, 2018
Company News

Tessa, St. Jude partner to develop cellular immunotherapies for pediatric brain cancers

...Tessa Therapeutics Pte. Ltd. (Singapore) and St. Jude Children's Research Hospital partnered to develop CAR-expressing virus-specific T cells to treat...
...company. Tessa Therapeutics Pte. Ltd., Singapore St. Jude Children's Research Hospital, Memphis, Tenn. Business: Cancer Mary Romeo Epstein-Barr Virus-Specific T Cells (EBVST) St. Jude Children's Research Hospital Tessa...
BioCentury | Aug 17, 2018
Company News

Mustang licenses immunodeficiency gene therapy from St. Jude

...commercialize an ex vivo lentiviral gene therapy to treat X-linked severe combined immunodeficiency (SCID) from St. Jude Children's Research Hospital...
...St. Jude Children's Research Hospital, Memphis, Tenn. Mustang Bio Inc. (NASDAQ:MBIO), New York, N.Y. Business: Gene/Cell therapy Sandi Wong Mustang Bio Inc. St. Jude Children's Research Hospital Interleukin-2...
Items per page:
1 - 10 of 165